Novel Treatment Regimen in the Neoadjuvant Setting with Trastuzumab Deruxtecan
This ongoing trial was presented at the American Society of Clinical Oncology (ASCO) Annual...
Read MoreJun 23, 2021
This ongoing trial was presented at the American Society of Clinical Oncology (ASCO) Annual...
Read MoreJun 17, 2021
Data indicate that many children with asthma have poorly controlled disease due to poor adherence with inhaled corticosteroids. To determine if an intervention can overcome this barrier, investigators administered a simplified...
Read MoreJun 17, 2021
While navigational bronchoscopy (NB) and convex-probe endobronchial ultrasound transbronchial needle aspiration (CP-EBUS-TBNA) are commonly performed in a single setting to evaluate suspicious pulmonary lesions, evidence...
Read MoreJun 17, 2021
Evidence shows that physical exercise can significantly improve exercise tolerance and quality of life in patients with systemic lupus erythematosus (SLE); however its impact on cardiorespiratory fitness in this patient...
Read MoreJun 17, 2021
Prior research suggest gender-specific differences in symptom levels and comorbidity prevalence among patients with COPD. Investigators conducted an analysis to determine whether the relationship between these characteristics is...
Read MoreJun 17, 2021
Although data indicate that e-cigarettes are the most commonly used tobacco product among adolescents and young adults (AYAs), frequent co-use with combustible cigarettes and cannabis products causes difficulty in disentangling...
Read MoreJun 17, 2021
Are you caught up on trials on tardive dyskinesia presented on APA 2021? Test your knowledge! 1. A...
Read MoreJun 16, 2021
Prior research provides unclear results on the benefits of omega-3 fatty acids for the prevention of cardiovascular outcomes in patients with high cardiovascular risk. To determine the association of plasma levels of...
Read MoreJun 16, 2021
United States guidelines suggest any aspirin dose between 81 mg and 325 mg daily for patients with coronary heart disease, while European guidelines that recommend 81 mg daily are mainly based on observational data and expert...
Read MoreJun 16, 2021
With little known regarding psychological distress and residual risk of future cardiovascular events in young and middle-aged patients with a recent myocardial infarction (MI), researchers divided patients aged 18-61 with an MI...
Read MoreJun 16, 2021
Previous studies suggest that endovascular renal denervation reduces blood pressure (BP) in patients with mild-to-moderate hypertension. However, its efficacy in patients with resistant hypertension remains unknow. To assess the...
Read MoreJun 16, 2021
Although research indicates that older adults hospitalized with acute decompensated heart failure (HF) have high rates of poor quality of life, delayed recovery, physical frailty, and frequent rehospitalization, well-established...
Read MoreJun 16, 2021
Earlier detection of primary ovarian tumor could extend survival in some patients When complete...
Read MoreJun 15, 2021
In the phase 2 NANT2011-01 trial, levels of circulating tumor DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time. Neuroblastoma is the most common extracranial...
Read MoreJun 15, 2021
Mirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial. Mirvetuximab soravtansine (MIRV) is...
Read MoreJun 15, 2021
First results from the phase 3 PEACE-1 trial show that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improves progression-free survival in patients who present with de novo metastatic...
Read MoreJun 15, 2021
First results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma. Lymphocyte-activation gene 3...
Read MoreJun 15, 2021
An exploratory post-hoc pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – shows longer overall survival for patients...
Read MoreJun 15, 2021
Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment. Gene signatures have proven successful in...
Read MoreJun 15, 2021
Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Read More